Medindia

X

Boston Scientific Announces Election of Ray Elliott to Its Board of Directors

Thursday, September 6, 2007 General News J E 4
Advertisement
NATICK, Mass., Sept. 6 Boston ScientificCorporation (NYSE: BSX) today announced that the Company's Board of Directorshas elected Ray Elliott as a Director.

Mr. Elliott, 58, is Chairman of the Board of Zimmer Holdings, Inc.Previously, he served as Chairman, President and Chief Executive Officer ofZimmer from 2001 to 2007 and President of Zimmer since 1997. Mr. Elliott hasextensive operating and director experience in medical devices, orthopaedicsand other industries. In 2005, Mr. Elliott was selected by InstitutionalInvestor Magazine as the "Best CEO in America" for Healthcare (MedicalSupplies and Devices).

Prior to his roles at Zimmer, Mr. Elliott was President and ChiefExecutive Officer of Cybex International, Inc. Before assuming his role atCybex, he was a President and Chief Operating Officer of Southam, Inc., andGroup President of John Labatt, Ltd. Previously, he served for 15 years in anumber of executive capacities with American Hospital Supply Corporation, apredecessor to Baxter International, including President of their Far Eastdivisions in Tokyo. He holds a B.A. from the University of Western Ontario.

"Ray is a highly regarded health care industry executive who hassuccessfully led complex global businesses for more than 20 years," said PeteNicholas, Chairman of the Board of Boston Scientific. "He has a keenunderstanding of the role of technology in improving health outcomes, and hewill bring a wealth of valuable experience to our board. We are pleased towelcome Ray to Boston Scientific."

With the election of Mr. Elliott, the Boston Scientific Board increases to15 members.

Boston Scientific is a worldwide developer, manufacturer and marketer ofmedical devices whose products are used in a broad range of interventionalmedical specialties. For more information, please visit:www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaningof Section 21E of the Securities Exchange Act of 1934. Forward-lookingstatements may be identified by words like "anticipate," "expect," "project,""believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates usinginformation available to us at the time and are not intended to be guaranteesof future events or performance. These forward-looking statements include,among other things, statements regarding our leadership, organizationalstructure, business strategy, financial performance, growth strategy, expensereduction initiatives and market position. If our underlying assumptions turnout to be incorrect, or if certain risks or uncertainties materialize, actualresults could vary materially from the expectations and projections expressedor implied by our forward-looking statements. These factors, in some cases,have affected and in the future (together with other factors) could affect ourability to implement our business strategy and may cause actual results todiffer materially from those contemplated by the statements expressed in thispress release. As a result, readers are cautioned not to place undue relianceon any of our forward-looking statements.

Factors that may cause such differences include, among other things:future economic, competitive, reimbursement and regulatory conditions; newproduct introductions; demographic trends; intellectual property; litigation;financial market conditions; and, future business decisions made by us and ourcompetitors. All of these factors are difficult or impossible to predictaccurately and many of them are beyond our control. For a further list anddescription of these and other important risks and uncertainties that mayaffect our future operations, see Part I, Item IA- Risk Factors in our mostrecent Annual Report on Form 10-K filed with th
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
American Oriental Bioengineering Completes Acquisi...
S
NPS Pharmaceuticals Commences Tender Offer for 3.0...